JAK Mutations are genetic abnormalities that affect the production of red blood cells. They are often found in individuals with polycythemia vera, as well as a number of other myeloproliferative neoplasms. The anti-PD-1 agent, Keytruda (pembrolizumab) was approved in 2014 by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Since then, it has received […]
Continue reading